The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...
Then yesterday, the FDA’s oncologic drugs advisory committee recommended approval of rituximab in a new subcutaneous formulation in a range of lymphomas and chronic lymphocytic leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback